Outcomes associated with introduction of thiazolidinedione therapy in Medicaid enrolled patients with type 2 diabetes: An updated and expanded retrospective analysis

Current Medical Research and Opinion

Volumn 22, Issue 3, 2006, Pages 551-559

  Balkrishnan, Rajesh ^a   Rajagopalan, Rukmini ^b   Shenolikar, Rahul A ^a   Camacho, Fabian T ^c   Anderson, Roger T ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b TAKEDA PHARMACEUTICALS   (United States)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

Low income; Medicated; Medication adherence; Pharmacotherapy cost analyses; Retrospective database analysis; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ORAL ANTIDIABETIC AGENT;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; RETROSPECTIVE STUDY; SCHOOL CHILD; SENSITIVITY ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; CHILD; DIABETES MELLITUS, TYPE 2; FEMALE; HEALTH CARE COSTS; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MEDICAID; MIDDLE AGED; NORTH CAROLINA; PATIENT COMPLIANCE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES; TREATMENT OUTCOME; UNITED STATES;

EID: 33645222224     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079906X96263     Document Type: Article

References (32)

1. American Diabetes Association, diabetes statistics. Available from http://www.diabetes.org/diabetes-statistics.jsp [Accessed 1 March 2004]
2. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes in the United States. Revised edition. Atlanta, GA: Centers for Disease Control and Prevention 2004. Available from http://www.diabetes.org/diabetes-statistics/national-diabetes- fact-sheet.jsp [Accessed 1 October 2005]
3. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14:S1-85
4. Hogan P, Dall T, Nikolov P; American Diabetes Association. Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917-32
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993;329:977-86
6. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53
7. Renders CM, Valk GD, Griffin SJ, et al. Interventions to improve the management of diabetes in primary care, outpatient, and community settings. Diabetes Care 2001;24:1821-33
8. O'Connor PJ, Spann S, Woolf S. Care of adults with type 2 diabetes mellitus. A review of the evidence. J Fam Pract 1998;47:S13-22
9. Stratton IM, Adler A, Neil H, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12
10. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999;281:2005-12
11. Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health care costs and utilization. JAMA 2001;285:182-9
12. DeFronzo R A. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303
13. Collins FM. Current treatment approaches to type 2 diabetes mellitus: successes and shortcomings. Am J Manag Care 2002;8: S460-71
14. Owens DR. Thiazolidinediones: a pharmacological overview. Clin Drug Inv 2002;22:485-505
15. Meriden T. Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther 2004;26:177-90
16. Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004;116:230-5
17. Bell DS. Type 2 diabetes mellitus: what is the optimal treatment regimen? Am J Med 2004;116:23S-9
18. Yanagawa T, Araki A, Sasamoto K, et al. Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism 2004;53:353-7
19. Dailey GE 3rd, Noor MA, Park JS, et al. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized, double-blind trial. Am J Med 2004;116:223-9
20. Campbell IW. Long-term glycaemic control with pioglitazone in patients with type 2 diabetes. Int J Clin Pract 2004;58:192-200
21. Coyle D, Palmer AJ, Tam R. Economic evaluation of pioglitazone hydrochloride in the management of type 2 diabetes mellitus in Canada. Pharmacoeconomics 2002;20:31-42
22. Chilcott J, Wight J, Lloyd Jones M, et al. The clinical effectiveness and cost-effectiveness of pioglitazone for type 2 diabetes mellitus: a rapid and systematic review. Health Technol Assess 2001;5:1-61
23. Piette JD, Heisler M, Wagner TH. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care 2004;27:384-91
24. Piette JD, Wagner TH, Potter MB, et al. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care 2004;42:102-9
25. Balkrishnan R, Rajagopalan R, Shenolikar RA, et al. Healthcare costs and prescription adherence with introduction of thiazolidinedione therapy in Medicaid type 2 diabetic patients: a retrospective data analysis. Curr Med Res Opin 2004;20: 1633-40
26. Balkrishnan R, Norwood GJ, Anderson A. Outcomes and cost benefits associated with the introduction of inhaled corticosteroid therapy in a Medicaid population of asthmatic patients. Clin Ther 1998;20:567-80
27. Balkrishnan R, Rajagopalan R, Camacho FT, et al. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther 2003;25:2958-71
28. Choo PW, Rand CS, Inui TS, et al. Validation of patient reports, automated pharmacy records, and pill counts with electronic monitoring of adherence to Antihypertensive therapy. Med Care 1999;37:846-57
29. Steiner JF, Koepsell TD, Fihn SD, et al. A general method of compliance assessment using centralized pharmacy records. Med Care 1988;26:814-23
30. Diggle P, Liang KY, Zeger SL. Analysis of longitudinal data. Oxford: Oxford University Press, 1994
31. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988;44:1049-60
32. Kennedy P. Estimation with correctly interpreted dummy variables in semilogarithmic equations. American Economic Review 1981;71:801